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Abstract It has previously been demonstrated that CuZn-
superoxide dismutase (SOD) is secreted by several human cell
lines. This suggests that the circulating enzyme derives from both
hemolysis and peripheral tissues as a result of cellular secretion.
In the present report, we evaluated the presence of CuZn-SOD in
human serum lipoproteins by both enzyme-linked immunosorbent
assay and Western blot analysis of immunoprecipitated lipopro-
tein samples. The distribution of CuZn-SOD activity among the
different lipoprotein fractions was also determined by the
xanthine/xanthine oxidase method. The results demonstrated
that CuZn-SOD is noticeably present in serum lipoproteins and
mainly in low and high density lipoproteins (LDL and HDL).
Moreover, experiments performed by incubating CuZn-SOD
with a lipid emulsion and subsequent separation of the lipid
fraction by ultracentrifugation showed that this enzyme associ-
ates in a saturable manner with lipids. The CuZn-SOD bound to
LDL and HDL could exert a physiological protective role
against oxidative damage of these lipoprotein classes that carry
out a crucial role in the cholesterol transport.
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1. Introduction
Among the antioxidant enzymatic systems, the superoxide
dismutase (SOD) isoenzymes are of crucial defense against the
reactive oxygen species (ROS) in eukaryotic cells. In mamma-
lians, there are three SODs (EC 1.15.1.1) : two intracellular
isoenzymes, the mitochondrial Mn-SOD [1] and the cytosolic
CuZn-SOD [2], and the extracellular SOD that is considered
the major isoenzyme in extracellular space [3]. Among these
enzymes which catalyze the dismutation of superoxide to
H2O2 and O2, the intracellular enzymes are expressed by all
cell types [4,5] whereas the extracellular SOD is less repre-
sented [6]. Until now, the only SOD isoenzyme thought to
be secreted by ¢broblasts and glial cells is the extracellular
type; our recent researches, however, showed that human ¢-
broblasts, hepatocarcinoma HepG2 [7], and human neuro-
blastoma SK-N-BE cells [8] are able to export the cytosolic
CuZn-SOD, suggesting an autocrine and/or a paracrine role
for this isoenzyme.
The presence of circulating CuZn-SOD, detected by di¡er-
ent methods, has so far been explained as deriving from phys-
iological red cells hemolysis. However, the existence of CuZn-
SOD secretion not restricted to speci¢c cell lines suggests that
serum CuZn-SOD can derive, at least partially, from periph-
eral tissues as a result of cellular secretion.
The presence of CuZn-SOD in human serum arises the
question whether and how this enzyme is transported into
the blood. It is known that circulating lipoproteins vehiculate
several substances [9]. Among them, there are also antioxi-
dants as vitamins A and E which carry out an important
protective e¡ect against lipoprotein oxidation. It is known
that low density lipoprotein (LDL) oxidation is an important
biochemical event leading to atherosclerosis [10,11] ; in fact,
oxidized LDL can be detected in atherosclerotic arterial tissue
[12] while the resistance of plasma LDL to oxidation is widely
assumed to be a good protective indicator against the athero-
genetic risk [13].
Here, we investigate whether, like A and E vitamins, the
serum CuZn-SOD is carried by circulating lipoproteins.
2. Materials and methods
2.1. Subjects
Ten healthy volunteers, three females and seven males (age 35^50
years), participated in this study giving their informed consent. The
subjects were fasted for 12 h before blood collection from a cubital
vein puncture.
The serum of each subject was separated after slight centrifugation
and 0.1% ethylenediaminetetraacetic acid (EDTA) disodium salt, 0.1%
of sodium azide and aprotinin (0.17 TIU/ml) were added in order to
prevent the bacterial degradation of proteins.
2.2. Lipoprotein preparation
The lipoprotein collection was performed according to the method
of Havel et al. [14]. Very low density (VLDL) and intermediate den-
sity lipoproteins (IDL), density 1.006^1.019 g/ml, LDL density 1.019^
1.063 g/ml and high density lipoproteins (HDL), density 1.063^1.210
g/ml, were isolated by a tube slicer after centrifugation at 40 000 rpm
at 14‡C in a 40.3 Beckman rotor for 18, 20 and 44 h for VLDL^IDL,
LDL and HDL, respectively.
The lipoprotein fractions and lipoprotein de¢cient serum (LPDS),
representing the bottom fraction obtained after HDL collection [14],
were then dialyzed for 24 h against NaCl 0.15 M in the presence of
0.1% EDTA disodium salt and 0.1% of sodium azide at 4‡C.
2.3. Enzyme activity assay
The SOD enzymatic activity was carried out by the cytochrome c,
xanthine/xanthine oxidase method of McCord and Fridovich [2]
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modi¢ed by Beyer et al. [15] using 50 mM HEPES, 0.1 mM EDTA,
pH 7.4, as assay bu¡er.
2.4. Enzyme-linked immunosorbent assay (ELISA)
ELISA for quantitative detection of human CuZn-SOD was carried
out using the Bender Med System kit (Bender Med System Diagnos-
tics GmbH, Vienna, Austria). CuZn-SOD concentrations in serum
and in LPDS were determined prediluting the samples 1:100 with
phosphate bu¡er, while the dilution of VLDL was 1:2 and that of
LDL and HDL was 1:10. The concentration of CuZn-SOD was de-
termined calculating the average absorbance (450 nm) values for each
sample and for the standard curve in duplicate. The detection limit of
the assay is 0.07 ng/ml. The intra-assay coe⁄cient of variation is 4%.
2.5. Polarographic method
CuZn-SOD was also determined by a polarographic method [16].
The SOD content is reported as ng of enzyme/ml with reference to the
activity in the same conditions of puri¢ed sample of human CuZn-
SOD. The catalytic constant of this enzyme as measured by polar-
ography was found to be 0.9U109 M31 s31.
2.6. Immunoprecipitation and Western blot of CuZn-SOD in
lipoproteins
The protein concentration of human serum lipoproteins was deter-
mined according to the method of Lowry et al. [17] using bovine
serum albumin (BSA) as standard. Lipoprotein samples (300 Wg) in
1 ml of bu¡er A (10 ml of Tris^HCl pH 7.4, 150 mM NaCl and 1 mM
EDTA) were immunoprecipitated for 1 h at 4‡C with rabbit polyclo-
nal anti-human CuZn-SOD (1:100 dilution) prepared as previously
described [18]. Protein A Sepharose (CL4B Sigma Chemical Com-
pany, St. Louis, MO, USA) was added to samples and continuously
stirred for 45 min at 4‡C.
After centrifugation in a microfuge at 3000 rpm for 10 min, Sephar-
ose pellets were washed once with 1 ml bu¡er A plus 1% Triton X-
100, 0.4 M NaCl and 0.5% BSA; then the pellets were washed again
with the same bu¡er plus 0.4 M NaCl and then with bu¡er A alone.
The Sepharose pellets were electrophoresed on a 12% sodium do-
decyl sulfate^polyacrylamide gel according to the method of Laemmli
[19] together with 25 Wg of commercial human erythrocyte CuZn-SOD
(Sigma Chemical Company, St. Louis, MO, USA) used as standard.
For Western blot experiments, a standard procedure was used utiliz-
ing enhanced chemiluminescence detection according to the manifac-
turer’s instructions (Amersham Life Science, UK). The primary rabbit
anti-human CuZn-SOD antibodies were the same utilized for the im-
munoprecipitation experiment at 1:2000 dilution; the secondary anti-
bodies, a horseradish peroxidase-linked donkey anti-rabbit IgG
(Amersham Life Science, UK), was instead diluted 1:5000. The detec-
tion limit for CuZn-SOD evaluation by Western blot experiments was
5 ng/ml and the intra-assay coe⁄cient of variation was 4.5%.
2.7. Incubation of CuZn-SOD with lipid emulsion
Lipid emulsion (CLINTEC Nutrition Clinique-Montargis, France)
obtained by high pressure homogenization was composed of 20% of
puri¢ed soy oil, 2.5% glycerol, 0.03% sodium oleate, 0.07% phospha-
tidylethanolamine, 0.01% lyso-phosphatidylethanolamine, 0.9% phos-
phatidylcholine, 0.022% sphingomyelin, 0.05% lyso-phosphatidylcho-
line, 6 0.02% glycerophosphorylcholine. The emulsion consists of a
vesicular dispersion containing a main population of small particles
with a mean diameter of 300 nm mixed with very small particles
(diameter less than 100 nm) accounting for only 3^6% of total.
75 Wl of the lipid emulsion was incubated with di¡erent amounts of
human CuZn-SOD dissolved in 6 ml of NaCl 0.15 M.
The lipid^CuZn-SOD mixture, incubated at room temperature for
30 min, was centrifuged at 30 000 rpm for 45 min in a 40.3 Beckman
rotor. The top layer and the bottom fractions were separated by tube
slicer and the activity of CuZn-SOD was evaluated by the cytochrome
c, xanthine/xanthine oxidase method.
2.8. Fluorimetric titration of a £uorescent probe with lipid emulsion
To evaluate whether the lipid emulsion was organized as a mixed
micelles association or as a vesicular dispersion, we utilized a £uori-
metric method [20] that uses 8-anilino-1-naphthalenesulfonic acid
magnesium salt (ANS) as £uorescent probe. Fluorimetric titration
was performed by adding increasing amounts of lipid emulsion to a
saline solution (0.15 M NaCl) containing 10 WM ANS. The excitation
and emission wavelengths were 375 and 520 nm, respectively.
3. Results
The CuZn-SOD distribution between serum and LPDS and
among the di¡erent lipoprotein classes was evaluated using
di¡erent methodologies.
Fig. 1A shows the CuZn-SOD serum concentration deter-
mined by an ELISA assay. The total serum enzyme concen-
tration is 115 þ 20 ng/ml (mean þ S.E.M., n = 10); 45 þ 3% of
CuZn-SOD is detectable in LPDS and the remaining part in
lipoproteins. Assuming as 100% the amount of CuZn-SOD
associated with lipoproteins, 50 þ 6% (mean þ S.E.M., n = 10)
of the enzyme is detected in LDL, 36 þ 2% in HDL and the
remaining part in VLDL^IDL (Fig. 1B). Further evidence
that CuZn-SOD is bound to serum lipoproteins is obtained
by immunoprecipitation experiments in which CuZn-SOD is
detected in all lipoprotein classes, even if a precise quanti¢ca-
tion from these data cannot be performed (Fig. 1C).
We also measured CuZn-SOD activity by the cytochrome c/
xanthine/xanthine oxidase method. Since this assay does not
allow to detect low CuZn-SOD activity values, in order to
evaluate the distribution of enzyme activity in human serum
Fig. 1. CuZn-SOD protein concentration determined by the ELISA
method in total and in LPDS (A). Values are expressed as percent
of total serum CuZn-SOD concentration (115 þ 20 ng/ml). In (B),
the CuZn-SOD distribution in lipoprotein fractions is expressed as
percent values assuming as 100% the amount of enzyme detected in
lipoproteins. The values are means þ S.E.M. (n = 10). In (C), the
Western blot of CuZn-SOD present in lipoproteins precipitated with
a rabbit polyclonal anti-human SOD is illustrated.
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lipoproteins, we incubated 4.5 ml of pooled human serum
with 200 U of this enzyme at 37‡C for 30 min, before starting
for lipoproteins isolation. The activity of CuZn-SOD in LPDS
is about 40 þ 3% (mean þ S.E.M., n = 3) of total serum CuZn-
SOD (Fig. 2A), showing that the main CuZn-SOD activity is
present in lipoproteins. Among lipoprotein classes, we have
observed the presence of CuZn-SOD activity mainly in LDL
(46 þ 5% of total lipoprotein content, mean þ S.E.M., n = 3).
The amount present in HDL and VLDL^IDL was 31 þ 5%
and 23 þ 4%, respectively (Fig. 2B). The CuZn-SOD concen-
tration in the same samples was also determined by ELISA
assay. The enzyme distribution in LPDS and lipoproteins was
45 þ 4% and 55 þ 6% (means þ S.E.M., n = 3), respectively. As-
suming as 100% the amount of CuZn-SOD associated with
lipoproteins, the percent values detected in lipoproteins were
20 þ 5, 43 þ 8 and 37 þ 6 (means þ S.E.M., n = 3) for VLDL^
IDL, LDL and HDL, respectively.
These results are further con¢rmed by the polarographic
method in which the enzyme activity in lipoprotein compared
to that recovered in LPDS shows a very similar distribution to
that obtained by either cytochrome c/xanthine/xanthine oxi-
dase and ELISA assays (45 þ 3% in LPDS; 55 þ 5% in serum
lipoproteins, means þ S.E.M., n = 10).
In order to evaluate whether CuZn-SOD has the ability to
bind the lipid component of lipoproteins, di¡erent amounts of
CuZn-SOD were incubated with lipid emulsion and further
ultracentrifuged to separate the lipids from the aqueous phase
(Fig. 3). At CuZn-SOD concentrations lower than 20 U, all
the enzyme added to lipid emulsion was detected in the top
lipid phase. As the CuZn-SOD concentration increases over
20 U, the enzyme activity is detected also in the bottom frac-
tion.
To evaluate the physical form of lipid emulsion association,
we performed a £uorimetric titration of the £uorescent probe
ANS with increasing lipid emulsion concentrations ranging
between 3U1034% and 5%; the higher concentration used
corresponds to that reached at the top layer obtained after
ultracentrifugation of the CuZn-SOD^lipid emulsion mixture.
The data obtained do not show the sharp increase of £uores-
cence emission characteristic of the phase transition corre-
sponding to mixed micelle formation; these data demonstrate
that the lipid emulsion interacts with CuZn-SOD in the form
of vesicular dispersion (data not shown). Consequently, we
strongly assume that CuZn-SOD is bound with the lipid emul-
sion by hydrophobic interaction.
4. Discussion
In this study, we show, for the ¢rst time, that serum CuZn-
SOD is bound to circulating lipoproteins. The analysis of
CuZn-SOD distribution between the di¡erent lipoprotein
classes shows that this enzyme is mainly bound to LDL and
HDL (density included between 1.019 and 1.210 g/ml) since
the CuZn-SOD amount present in VLDL^IDL was about
20% of the total CuZn-SOD lipoprotein content.
This ¢nding has relevant physiological implications. In fact,
ROS mediating lipid peroxidation of LDL are considered to
have a key role in the pathogenesis of atherosclerosis. Oxi-
dized LDLs have an increased half life and are preferentially
recognized by scavenger receptors which, unlike the B/E re-
ceptor, are not subjected to down-regulation [21], leading to
foam cells formation. It is known that LDL represents the
principal form of transport of vitamin A and E [22,23] and
the presence of these antioxidants has been positively corre-
lated with increased resistance to the oxidative modi¢cation of
Fig. 2. CuZn-SOD activity determined in total and in LPDS (A).
Values are expressed as percent of total serum CuZn-SOD activity.
In (B), the CuZn-SOD activity distribution in lipoprotein fractions
is expressed as percent values assuming as 100% the amount of en-
zyme activity detected in lipoproteins. These values (means þ S.E.M.,
n = 3) were obtained incubating 4.5 ml of serum with 200 U of
CuZn-SOD at 37‡C for 30 min before starting the lipoprotein col-
lection.
Fig. 3. CuZn-SOD activity in the top and bottom fractions (infra-
nate) obtained by ultracentrifugation of a lipid emulsion preincu-
bated with an increasing amount of enzyme. SOD activity was
measured by the cytochrome c/xanthine/xanthine oxidase method.
Values are means þ S.E.M. of three experiments performed in dupli-
cate.
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LDL. An enhanced resistance to oxidation of LDL and a
decreased lipid peroxidation have been shown to occur during
L carotene supplementation to patients a¡ected by cystic ¢-
brosis in which a severe L carotene de¢ciency is demonstrated
[24]. The presence of CuZn-SOD in circulating LDL could
carry out, like vitamins A and E, an important role limiting
the oxidative modi¢cation of this lipoprotein; in particular, it
could exert a speci¢c role protecting these particles from
superoxide-mediated lipid peroxidation [25,26]. There are, in
fact, several evidences of O32 involvement in the LDL oxida-
tion mechanism: (i) endothelial cells have been demonstrated
to produce both nitric oxide and superoxide that represent
potent LDL oxidants [27]; (ii) cultured smooth cells and en-
dothelial cells stimulate O32 -mediated LDL oxidation in the
presence of transitional metals that are reduced by O32 [28] ;
(iii) the addition of CuZn-SOD in vitro inhibits monocyte-
mediated LDL oxidation [29].
Some recent data showed that the oxidative susceptibility of
LDL in vitro and in vivo is in£uenced by HDL. This lipopro-
tein, which is involved in the reverse cholesterol transport [30],
has been reported to exhibit an antioxidant e¡ect since oxi-
dative modi¢cation occurs more slowly in LDL^HDL mix-
tures than in LDL alone [9,31^34]. Using the oxidation-labile
£uorescent probe parinaric acid cholesteryl ester, direct evi-
dence has been given that HDL inhibits both Cu- and Fe2-
induced peroxidation of LDL-associated lipids [35]. The pres-
ence of transition metals is fundamental for in vitro LDL
oxidation as demonstrated by the inhibition of lipoprotein
peroxidation by metal chelators [29]. A possible mechanism
for the antioxidant e¡ects of HDL has been related to inhibi-
tion of transitional metal catalyzing reactions due to the pres-
ence of transferrin and ceruloplasmin in apo AI containing
lipoproteins [9]. The presence of CuZn-SOD in HDL can, at
least partially, account for the antioxidant e¡ect of this lipo-
protein class.
Finally, in addition to the presence of CuZn-SOD in circu-
lating lipoproteins, we clearly demonstrated that CuZn-SOD
interacts in a saturable manner with emulsi¢ed lipids; when 20
U of CuZn-SOD was added to the lipid emulsion, all the
enzyme activity was recovered in the lipid top layer separated
from the aqueous phase by ultracentrifugation. Since the lipid
emulsion used for such experiments is organized as vesicular
dispersion, we can assume that CuZn-SOD associates with
lipids by a simple hydrophobic interaction. These data suggest
that CuZn-SOD is bound to the lipid component of lipopro-
teins. However, further studies could better clarify the associ-
ation of CuZn-SOD with speci¢c lipid components of lipo-
proteins and evaluate the existence of an interaction with the
apoprotein component of lipoproteins.
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